Global Leading Market Research Publisher QYResearch announces the release of its latest report “Specialty Biopharmaceutical Excipients – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Specialty Biopharmaceutical Excipients market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Specialty Biopharmaceutical Excipients was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Addressing Core Biologic Drug Formulation, Protein Stability, and Parenteral Delivery Pain Points
Biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and formulation scientists face persistent challenges: biologic drugs (monoclonal antibodies (mAbs), recombinant proteins, vaccines, gene therapies, cell therapies) require specialized excipients for stability (prevent aggregation, denaturation, oxidation), solubility (high concentration formulations), and delivery (parenteral, subcutaneous, intravenous, intramuscular). Traditional small molecule excipients (fillers, binders, disintegrants) are insufficient for complex biologics. Specialty biopharmaceutical excipients—expanding agents (lyoprotectants), solubility enhancers (surfactants, cyclodextrins), and protein stabilizers—have emerged as critical components for biologic formulation. However, product selection is complicated by four distinct excipient types: expanding agent (bulking agent for lyophilization), solubility enhancer (improves drug solubility), surfactant (prevents protein aggregation, surface adsorption), and others (antioxidants, chelating agents, preservatives). Over the past six months, new biologic drug approvals (mAbs, ADCs, gene therapies), high-concentration subcutaneous formulations, and mRNA vaccine expansion have reshaped the competitive landscape.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6016969/specialty-biopharmaceutical-excipients
Key Industry Keywords (Embedded Throughout)
- Specialty biopharmaceutical excipients
- Expanding agent solubility
- Surfactant protein stabilization
- Oral medication injection
- Biologic drug formulation
Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026)
The global specialty biopharmaceutical excipients market is concentrated among global excipient manufacturers and specialty chemical companies. Key players include Merck KGaA (Germany), Signet Excipients Pvt. Ltd (India), Sigachi Industries Limited (India), Associated British Foods plc (UK), Spectrum Chemical Manufacturing Corp. (US), Roquette Freres (France), IMCD (Netherlands), Clariant (Switzerland), DFE Pharma (Germany), Colorcon (US), BASF (Germany), Evonik Industries (Germany), and J. RETTENMAIER & SOHNE GmbH (Germany).
Three recent developments are reshaping demand patterns:
- Biologic drug market growth: Global biologics market reached $450B+ in 2025 (mAbs, ADCs, fusion proteins, gene therapies, mRNA vaccines). Specialty excipients (polysorbate 80/20, trehalose, sucrose, histidine, arginine) demand grew 8-10% annually.
- High-concentration subcutaneous formulations: Patient preference for subcutaneous self-administration (vs. IV infusion) requires high-concentration mAb formulations (>100 mg/mL). Surfactants (polysorbate) and solubility enhancers (arginine, proline) prevent aggregation and viscosity issues.
- mRNA vaccine and gene therapy expansion: mRNA vaccines (COVID-19, influenza, RSV) and lipid nanoparticles (LNPs) require specialty excipients (ionizable lipids, PEGylated lipids, cholesterol). LNP excipient demand grew 15-20% in 2025.
Technical Deep-Dive: Specialty Excipient Types
- Expanding Agent (bulking agent for lyophilization/freeze-drying). Examples: trehalose, sucrose, mannitol, glycine. Advantages: provides structural support to protein cake, prevents collapse, and stabilizes protein during freeze-drying (removes water, reduces degradation). A 2025 study from the Journal of Pharmaceutical Sciences found that trehalose is superior to sucrose for protein stabilization (lower aggregation after lyophilization and reconstitution). Accounts for approximately 20-25% of specialty biopharmaceutical excipient market value.
- Solubility Enhancer (improves drug solubility in aqueous formulations). Examples: cyclodextrins (hydroxypropyl-beta-cyclodextrin (HPβCD), sulfobutylether-beta-cyclodextrin (SBE-β-CD)), arginine, proline, nicotinamide. Advantages: enables high-concentration formulations (subcutaneous delivery), improves bioavailability of poorly soluble small molecules (in ADCs). Accounts for approximately 25-30% of market value.
- Surfactant (prevents protein aggregation, surface adsorption, and interfacial stress). Examples: polysorbate 20 (Tween 20), polysorbate 80 (Tween 80), poloxamer 188. Advantages: protects mAbs and recombinant proteins from agitation, freeze-thaw, and shipping stress. Polysorbate degradation (oxidation, hydrolysis) is a major stability concern; newer alternatives (poloxamer) are emerging. Accounts for approximately 30-35% of market value (largest segment).
- Others (antioxidants (methionine, glutathione), chelating agents (EDTA), preservatives (benzyl alcohol, phenol), buffering agents (histidine, citrate, succinate)). Accounts for 15-20% of market value.
User case example: In November 2025, a biopharmaceutical manufacturer (mAb, 10,000 L bioreactor) published results from optimizing formulation with specialty excipients (surfactants, solubility enhancers) for high-concentration subcutaneous delivery (150 mg/mL). The 12-month study (completed Q1 2026) showed:
- mAb concentration: 150 mg/mL (vs. 50 mg/mL for IV infusion).
- Excipients: polysorbate 80 (surfactant), arginine (solubility enhancer), histidine (buffer), sucrose (lyoprotectant).
- Aggregation: <1% (polysorbate 80 prevented aggregation).
- Viscosity: 15 cP (arginine reduced viscosity at high concentration).
- Stability: 24 months at 2-8°C (polysorbate 80, sucrose).
- Decision: Surfactant (polysorbate 80) + solubility enhancer (arginine) for high-concentration subcutaneous mAb.
Industry Segmentation: Discrete vs. Continuous Manufacturing
- Specialty excipient manufacturing (polysorbate synthesis, trehalose fermentation, cyclodextrin enzymatic production) follows batch chemical manufacturing (high purity, low bioburden).
- Polysorbate production (ethoxylated sorbitan fatty acid esters) is continuous or batch.
Exclusive observation: Based on analysis of early 2026 product launches, a new “polysorbate-free surfactant” (poloxamer 188, poloxamer 407, P188) is emerging for mAb formulations to address polysorbate degradation (oxidation, hydrolysis, particle formation). Polysorbate degradation leads to visible particles, immunogenicity risk, and product recalls. Poloxamer 188 is more stable (no ester bonds) and has been approved in several biosimilar formulations. Poloxamer-based surfactants command 20-30% price premium ($500-1,000/kg vs. $50-100/kg for polysorbate 80).
Application Segmentation: Oral Medication, Injection Medicine, Other
- Oral Medication (tablets, capsules, solutions, suspensions for small molecules, peptides) accounts for 30-35% of specialty biopharmaceutical excipient market value. Expanding agents (mannitol, lactose), solubility enhancers (cyclodextrins), surfactants.
- Injection Medicine (parenteral: IV infusion, subcutaneous, intramuscular, intradermal) accounts for 50-55% of value (largest segment). Surfactants (polysorbate 80/20, poloxamer 188), solubility enhancers (arginine, proline, cyclodextrins), expanding agents (trehalose, sucrose). Fastest-growing segment (8-10% CAGR), driven by mAbs, ADCs, gene therapies, mRNA vaccines.
- Other (topical, ophthalmic, nasal, inhalation) accounts for 10-15% of value.
Strategic Outlook & Recommendations
The global specialty biopharmaceutical excipients market is projected to reach US$ million by 2032, growing at a CAGR of %.
- Biopharmaceutical formulation scientists: Surfactants (polysorbate 80/20, poloxamer 188) for mAb stability (prevent aggregation, surface adsorption). Solubility enhancers (arginine, proline, cyclodextrins) for high-concentration subcutaneous formulations (>100 mg/mL). Expanding agents (trehalose, sucrose) for lyophilized products (freeze-dried mAbs, vaccines). Poloxamer 188 as polysorbate-free alternative (degradation-resistant).
- CDMOs and contract manufacturers: Specialty excipient supply chain reliability (polysorbate 80 shortages in 2020-2022). Dual sourcing (polysorbate + poloxamer) for risk mitigation.
- Manufacturers (Merck, BASF, Evonik, Roquette, DFE Pharma, Colorcon, IMCD, Clariant, JRS, Spectrum, Signet, Sigachi): Invest in polysorbate-free surfactants (poloxamer 188, poloxamer 407), high-purity trehalose (low endotoxin, low bioburden for parenteral), and cyclodextrins (HPβCD, SBE-β-CD) for solubility enhancement.
For biologic drug formulation (mAbs, recombinant proteins, mRNA vaccines, gene therapies), specialty biopharmaceutical excipients (surfactants, solubility enhancers, expanding agents) are essential for stability, solubility, and delivery. Surfactants (polysorbate 80/20) dominate mAb formulations; polysorbate-free alternatives (poloxamer 188) emerging. Injection medicine (parenteral) is largest and fastest-growing segment, driven by high-concentration subcutaneous mAbs and mRNA vaccines.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
